GO:0002931 response to ischemia: Cellular Stress Response, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002931 response to ischemia describes any process that changes an organism's state or activity due to inadequate blood supply, encompassing transcriptional, metabolic, and signaling adaptations.
• Ischemia triggers accumulation of succinate, which drives mitochondrial reactive oxygen species (ROS) production upon reperfusion, a central mechanism of reperfusion injury.
• Endothelial necroptosis under ischemic conditions can induce hemolysis and angiopathy, linking ischemia to vascular pathology in diseases such as COVID-19.
• Epigenetic regulators modulate the revascularization response to chronic arterial occlusion, highlighting the role of chromatin-modifying enzymes in ischemic adaptation.
• Ischemic injury is relevant across diverse clinical contexts, including stroke, polytrauma, retinal ischemia, and xenotransplantation.
• Hypoxia-responsive probes and AIEgens are emerging tools for precise disease theranostics in ischemic conditions.
Description
Ischemia, defined as inadequate blood supply to a tissue, initiates a complex biological program known as the response to ischemia (GO:0002931). This process encompasses changes in gene expression, metabolism, and cellular signaling that aim to restore homeostasis or, when prolonged, lead to irreversible injury. The response to ischemia is a fundamental biological process studied across organ systems, from the heart and brain to the kidney and retina. Understanding its molecular underpinnings is critical for developing therapies for stroke, myocardial infarction, and other ischemic diseases. Recent research has identified key mediators such as succinate accumulation, mitochondrial ROS, and endothelial necroptosis, providing mechanistic insights into ischemia-reperfusion injury. Moreover, epigenetic regulators and hypoxia-responsive probes are expanding the toolkit for studying and targeting ischemic responses. This article synthesizes current knowledge on GO:0002931, covering its definition, core mechanisms, key genes, disease relevance, and research methodologies, with a focus on CRISPR-based models for functional interrogation.
response to ischemia At A Glance
| GO ID | GO:0002931 |
|---|---|
| GO term | response to ischemia |
| Ontology | biological_process |
| Synonym | None |
| Major function | Cellular and systemic adaptation to inadequate blood supply, involving metabolic, transcriptional, and signaling changes |
| Key triggers | Reduced oxygen and nutrient delivery, accumulation of metabolites such as succinate |
| Major pathways | Mitochondrial ROS production, necroptosis, epigenetic regulation, revascularization |
| Disease relevance | Stroke, myocardial infarction, polytrauma, retinal ischemia, COVID-19 angiopathy |
What Is GO:0002931?
GO:0002931 response to ischemia is defined as any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of inadequate blood supply. This biological process captures the organism's adaptive and maladaptive reactions to reduced perfusion, including metabolic shifts, inflammatory signaling, and cell death pathways.
Why Is response to ischemia Important in Cell Biology?
The response to ischemia is a central mechanism in numerous acute and chronic diseases, including stroke, myocardial infarction, and peripheral artery disease. It determines tissue survival and functional recovery after ischemic insults, and its dysregulation contributes to reperfusion injury, a major cause of morbidity following revascularization. Understanding GO:0002931 is therefore essential for identifying therapeutic targets and developing interventions that mitigate ischemic damage.
• Ischemia-reperfusion injury is a leading cause of tissue damage in stroke and myocardial infarction.
• Succinate accumulation during ischemia drives mitochondrial ROS production upon reperfusion, a key therapeutic target.
• Endothelial necroptosis under ischemia contributes to hemolysis and vascular pathology in COVID-19.
• Epigenetic regulators influence the revascularization response to chronic arterial occlusion.
• Ischemic responses are relevant to polytrauma and systemic inflammatory states.
• Retinal ischemia models reveal rod-cone differences in susceptibility, informing neuroprotective strategies.
• Hypoxia-responsive AIEgens enable precise imaging and theranostics in ischemic diseases.
• Xenotransplantation studies highlight immune and ischemic responses in pig-to-human kidney transplants.
• Stroke-specific quality of life scales underscore the clinical impact of ischemic brain injury.
• CRISPR screening can identify novel regulators of the ischemic response for therapeutic development.
What Happens During response to ischemia?
Metabolic Shift and Succinate Accumulation
In simple terms: When blood supply is cut off, cells switch their metabolism and build up a molecule called succinate.
During ischemia, oxygen deprivation forces cells to rely on anaerobic metabolism, leading to the accumulation of succinate, a tricarboxylic acid (TCA) cycle intermediate. This succinate buildup is a hallmark of ischemic tissues and serves as a substrate for reverse electron transport at complex I upon reperfusion, driving a burst of mitochondrial reactive oxygen species (ROS). The metabolic shift also involves changes in enzyme production and gene expression, as the organism attempts to adapt to inadequate blood supply.
Mitochondrial ROS Production and Reperfusion Injury
In simple terms: When blood flow returns, the built-up succinate causes mitochondria to produce harmful oxygen radicals.
Upon reperfusion, the accumulated succinate is rapidly oxidized, driving reverse electron transport through mitochondrial complex I and generating a large burst of ROS. This ROS burst is a primary cause of reperfusion injury, leading to oxidative damage, cell death, and inflammation. The mechanism links ischemic metabolite accumulation directly to post-ischemic tissue damage, making it a target for therapeutic intervention.
Endothelial Necroptosis and Vascular Dysfunction
In simple terms: Ischemia can cause the cells lining blood vessels to die in a programmed way, leading to red blood cell breakdown.
Ischemic conditions can trigger necroptosis, a programmed form of necrosis, in endothelial cells. This endothelial necroptosis induces hemolysis and contributes to angiopathy, as observed in COVID-19. The process involves specific signaling pathways that lead to membrane rupture and release of damage-associated molecular patterns, exacerbating vascular injury.
Epigenetic Regulation of Revascularization
In simple terms: Cells can change how their DNA is read to help grow new blood vessels after chronic ischemia.
In response to chronic arterial occlusion, epigenetic regulators modulate the revascularization response. These regulators influence gene expression programs that promote angiogenesis and arteriogenesis, helping to restore blood flow to ischemic tissues. The identification of epigenetic enzymes involved in this process offers potential targets for therapeutic revascularization.
Tissue-Specific Responses: Retinal Ischemia
In simple terms: Different cell types in the eye respond differently to lack of blood supply.
In the retina, rods and cones exhibit differences in their response to ischemia. This differential susceptibility is relevant to understanding ischemic retinopathies and developing neuroprotective strategies. The rabbit model of retinal ischemia has been used to characterize these cell-type-specific responses.
Key Genes Involved in GO:0002931 response to ischemia
The following genes and proteins are key players in the response to ischemia, as identified in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SDHA | Succinate dehydrogenase subunit A; involved in succinate accumulation during ischemia | Target for modulating mitochondrial ROS in reperfusion injury |
| NDUFS1 | NADH:ubiquinone oxidoreductase core subunit S1; complex I subunit driving reverse electron transport | Key mediator of ROS burst upon reperfusion |
| RIPK1 | Receptor-interacting serine/threonine kinase 1; regulator of necroptosis | Mediates endothelial necroptosis in ischemic angiopathy |
| RIPK3 | Receptor-interacting serine/threonine kinase 3; necroptosis executioner | Involved in ischemic endothelial cell death |
| MLKL | Mixed lineage kinase domain like pseudokinase; necroptosis effector | Executes membrane rupture in ischemic necroptosis |
| HIF1A | Hypoxia inducible factor 1 subunit alpha; master regulator of hypoxia response | Central to transcriptional adaptation to ischemia |
| VEGFA | Vascular endothelial growth factor A; promotes angiogenesis | Therapeutic target for revascularization |
| EPAS1 | Endothelial PAS domain protein 1; hypoxia-inducible factor 2 alpha | Regulates endothelial response to ischemia |
| KDM6A | Lysine demethylase 6A; epigenetic regulator | Modulates revascularization response |
| HDAC9 | Histone deacetylase 9; epigenetic regulator | Influences ischemic angiogenesis |
| CASP8 | Caspase 8; apoptosis and necroptosis initiator | Modulates cell death pathways in ischemia |
| TNF | Tumor necrosis factor; inflammatory cytokine | Triggers necroptosis in ischemic endothelium |
| IL6 | Interleukin 6; inflammatory cytokine | Contributes to ischemic inflammation |
| CXCL8 | C-X-C motif chemokine ligand 8; neutrophil chemoattractant | Mediates inflammatory response in polytrauma and ischemia |
| SLC2A1 | Solute carrier family 2 member 1; glucose transporter | Adapts cellular metabolism to ischemia |
| LDHA | Lactate dehydrogenase A; anaerobic glycolysis enzyme | Supports anaerobic metabolism during ischemia |
| BNIP3 | BCL2 interacting protein 3; mitophagy regulator | Modulates mitochondrial quality control in ischemia |
| PINK1 | PTEN induced kinase 1; mitophagy regulator | Protects against ischemic mitochondrial damage |
How Is response to ischemia Regulated?
The response to ischemia is regulated at multiple levels, including transcriptional activation by hypoxia-inducible factors (HIFs), epigenetic modifications by histone demethylases and deacetylases, and post-translational modifications such as phosphorylation in necroptosis signaling. Metabolic feedback, particularly succinate accumulation, directly influences mitochondrial ROS production and downstream signaling. These regulatory layers integrate to determine cell survival or death under ischemic conditions.
response to ischemia and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SDHA | Reperfusion injury in myocardial infarction and stroke | Knockout or point mutation in cardiomyocytes or neurons to assess succinate accumulation |
| RIPK1 | COVID-19 angiopathy and endothelial necroptosis | Endothelial cell knockout to block necroptosis and hemolysis |
| HIF1A | Ischemic stroke and hypoxia adaptation | Knockout or overexpression in neuronal cells to study transcriptional response |
| KDM6A | Peripheral artery disease and impaired revascularization | Knockout in endothelial cells to assess angiogenesis |
| VEGFA | Chronic arterial occlusion and therapeutic angiogenesis | Overexpression in ischemic tissue models to promote revascularization |
Ischemic Stroke and Neurodegeneration
Ischemic stroke is a leading cause of disability and mortality, and the response to ischemia in the brain determines neurological outcome. The accumulation of succinate and subsequent mitochondrial ROS production contributes to reperfusion injury after stroke. Stroke-specific quality of life scales have been developed to assess patient outcomes, underscoring the clinical importance of ischemic brain injury.
Cardiovascular Disease and Myocardial Infarction
In myocardial infarction, the response to ischemia and subsequent reperfusion injury causes cardiomyocyte death and heart failure. Succinate-driven ROS production is a key mechanism of cardiac reperfusion injury, and targeting this pathway is a promising therapeutic strategy. Chronic arterial occlusion also triggers revascularization responses regulated by epigenetic factors.
COVID-19 Angiopathy and Endothelial Dysfunction
Ischemic endothelial necroptosis has been implicated in COVID-19 angiopathy, where it induces hemolysis and vascular damage. This highlights the role of the ischemic response in infectious disease-associated vascular pathology. Understanding these mechanisms may inform therapies for COVID-19 and other conditions with endothelial injury.
Polytrauma and Systemic Ischemia
Polytrauma often involves systemic ischemia and reperfusion, leading to a systemic inflammatory response and multiple organ failure. The pathophysiology includes activation of inflammatory cytokines and chemokines, such as IL6 and CXCL8, which are part of the ischemic response. Managing the ischemic component is critical in trauma care.
From response to ischemia-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SDHA reduce succinate accumulation and reperfusion injury? | SDHA knockout cell line (e.g., cardiomyocytes) |
| Can a point mutation in NDUFS1 prevent reverse electron transport? | NDUFS1 point-mutation knock-in cells |
| Does RIPK1 kinase-dead knock-in block endothelial necroptosis? | RIPK1 point-mutation knock-in endothelial cells |
| What is the effect of HIF1A overexpression on ischemic tolerance? | HIF1A overexpression cell model |
| Can tagged KDM6A be used to map chromatin binding in ischemia? | Tagged knock-in of KDM6A in endothelial cells |
| Does knockout of MLKL protect against ischemic hemolysis? | MLKL knockout endothelial cells |
How to Study the response to ischemia Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identifying HIF targets and epigenetic regulators in ischemia |
| ChIP-seq | Chromatin binding of transcription factors and histone marks | Mapping epigenetic regulation of revascularization |
| LC-MS metabolomics | Metabolite levels including succinate | Quantifying succinate accumulation during ischemia |
| Seahorse respirometry | Mitochondrial oxygen consumption and ROS | Assessing reverse electron transport in reperfusion injury |
| Western blot | Protein expression and phosphorylation | Detecting necroptosis markers like pMLKL |
| Hemolysis assay | Red blood cell lysis | Evaluating endothelial necroptosis-induced hemolysis |
| Hypoxia-responsive AIEgen imaging | Hypoxic tissue distribution | Theranostics in ischemic disease models |
| Electroretinography | Retinal neuronal function | Assessing retinal ischemia in rabbit models |
Transcriptomic and Epigenomic Profiling
RNA sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) are used to profile gene expression and epigenetic changes during the response to ischemia. These methods identify hypoxia-inducible factor targets and epigenetic regulators that modulate revascularization. Single-cell RNA-seq can resolve cell-type-specific responses, such as rod versus cone differences in retinal ischemia.
Metabolomics and Mitochondrial Function Assays
Metabolomic profiling, including liquid chromatography-mass spectrometry (LC-MS), quantifies succinate and other metabolites during ischemia and reperfusion. Mitochondrial function is assessed using Seahorse respirometry and ROS-sensitive dyes to measure reverse electron transport and ROS production. These techniques are essential for validating metabolic mechanisms of ischemic injury.
Cell Death and Necroptosis Assays
Necroptosis is measured by detecting phosphorylated MLKL, RIPK1/RIPK3 complexes, and membrane permeability using western blotting and imaging. Hemolysis assays quantify red blood cell breakdown in endothelial necroptosis models. These methods help dissect the contribution of necroptosis to ischemic angiopathy.
Imaging and Theranostics
Hypoxia-responsive AIEgens enable real-time imaging of ischemic tissues and can be used for theranostic applications. Intravital microscopy and laser Doppler perfusion imaging assess revascularization in chronic arterial occlusion models. Retinal ischemia models use electroretinography and histology to evaluate neuronal survival.
How CRISPR Can Be Used to Study GO:0002931 response to ischemia
Knockout
CRISPR knockout is used to delete genes such as SDHA, RIPK1, or MLKL to determine their causal role in the ischemic response. For example, SDHA knockout can reduce succinate accumulation and protect against reperfusion injury. Knockout of RIPK1 or MLKL blocks endothelial necroptosis and hemolysis in ischemic models.
Point Mutation
Point mutations can be introduced to dissect specific residues required for ischemic signaling. For instance, a kinase-dead mutation in RIPK1 can distinguish its scaffolding versus kinase functions in necroptosis. Similarly, point mutations in NDUFS1 can test the requirement for reverse electron transport in ROS production.
Knock-in
Knock-in of tagged proteins, such as GFP-tagged KDM6A, allows chromatin binding studies in ischemic endothelial cells. Knock-in of reporter genes under hypoxia-responsive promoters enables live imaging of ischemic responses. These models provide spatial and temporal resolution of gene function.
Overexpression
Overexpression of protective genes like HIF1A or VEGFA can enhance ischemic tolerance and revascularization. CRISPR activation (CRISPRa) enables targeted overexpression without genomic integration, useful for screening protective factors. Overexpression models help identify therapeutic candidates for ischemic diseases.
How EDITGENE Supports response to ischemia Research
Researchers studying response to ischemia-related genes often need to determine whether a candidate gene is causally involved in ischemic injury or adaptation. EDITGENE provides comprehensive CRISPR-based services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as library screening and bioinformatics support, enabling rigorous functional studies of GO:0002931.
Contact EDITGENE today to design your custom CRISPR model for response to ischemia research.
Frequently Asked Questions About response to ischemia
What is GO:0002931 response to ischemia?
GO:0002931 is a Gene Ontology biological process term defined as any process that results in a change in state or activity of an organism as a result of inadequate blood supply. It includes metabolic, transcriptional, and signaling adaptations to ischemia.
What genes are involved in response to ischemia?
Key genes include SDHA and NDUFS1 in mitochondrial metabolism, RIPK1, RIPK3, and MLKL in necroptosis, and HIF1A, VEGFA, and KDM6A in transcriptional and epigenetic regulation.
How does succinate contribute to ischemia-reperfusion injury?
During ischemia, succinate accumulates and upon reperfusion drives reverse electron transport at complex I, producing a burst of mitochondrial ROS that causes tissue damage.
What is the role of necroptosis in ischemic endothelial injury?
Ischemia can trigger necroptosis in endothelial cells, leading to hemolysis and angiopathy, as seen in COVID-19.
Which diseases are associated with response to ischemia?
Ischemic stroke, myocardial infarction, peripheral artery disease, polytrauma, retinal ischemia, and COVID-19 angiopathy are associated with the response to ischemia.
How can CRISPR be used to study response to ischemia?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of genes involved in ischemic injury and adaptation.
What methods are used to study response to ischemia?
Common methods include RNA-seq, ChIP-seq, metabolomics, Seahorse respirometry, western blotting, and hypoxia-responsive imaging.
What is the role of HIF1A in ischemia?
HIF1A is a master transcriptional regulator of hypoxia responses, controlling genes that promote adaptation to low oxygen and revascularization.
How do epigenetic regulators affect revascularization after ischemia?
Epigenetic enzymes such as KDM6A and HDAC9 modulate gene expression programs that drive angiogenesis and arteriogenesis in response to chronic arterial occlusion.
Can EDITGENE help create ischemic disease models?
Yes, EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to model and study response to ischemia.
Conclusion
GO:0002931 response to ischemia is a fundamental biological process with broad relevance to human disease, from stroke and myocardial infarction to COVID-19 angiopathy and polytrauma. Mechanistic studies have identified succinate accumulation, mitochondrial ROS, necroptosis, and epigenetic regulation as key nodes. CRISPR-based models are indispensable for dissecting these pathways and identifying therapeutic targets. EDITGENE provides comprehensive services to accelerate research on the ischemic response, enabling functional validation of candidate genes and discovery of novel interventions.
References
- 1. Loupy A et al.. 2023. Immune response after pig-to-human kidney xenotransplantation: a multimodal phenotyping study.. Lancet 402(10408):1158-1169 PMID: 37598688
- 2. Chouchani ET et al.. 2014. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS.. Nature 515(7527):431-435 PMID: 25383517
- 3. Williams LS et al.. 1999. Development of a stroke-specific quality of life scale.. Stroke 30(7):1362-9 PMID: 10390308
- 4. Wu MCL et al.. 2025. Ischaemic endothelial necroptosis induces haemolysis and COVID-19 angiopathy.. Nature 643(8070):182-191 PMID: 40468079
- 5. Keel M et al.. 2005. Pathophysiology of polytrauma.. Injury 36(6):691-709 PMID: 15910820
- 6. Liu D et al.. 2024. Hypoxia-responsive AIEgens for precise disease theranostics.. Luminescence 39(1):e4659 PMID: 38286609
- 7. Heuslein JL et al.. 2019. Epigenetic regulators of the revascularization response to chronic arterial occlusion.. Cardiovasc Res 115(4):701-712 PMID: 30629133
- 8. Brunette JR et al.. 1986. Rod-cone differences in response to retinal ischemia in rabbit.. Doc Ophthalmol 63(4):359-65 PMID: 3803167
